|View printer-friendly version|
|LabCorp Completes Acquisition of Chiltern|
Strengthens LabCorp’s Position as a
“The addition of Chiltern advances a key element of LabCorp’s strategy –
to bring innovative medicines to patients faster which ultimately will
improve patient outcomes,” said
The Covance executive team will be integrated with Chiltern members immediately and will comprise existing leaders from both companies.
“The powerful combination of Covance and Chiltern enables us to provide
enhanced customer offerings including expanded functional service
provider solutions and leading oncology expertise,” said
Chiltern’s forecasted 2017 revenue and adjusted EBITDA are approximately
LabCorp (NYSE: LH), an
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements including with respect to Chiltern’s forecasted 2017 revenue and adjusted EBITDA, expectations regarding Chiltern’s impact on adjusted earnings per share and free cash flow, and expected leadership, benefits, growth, innovation, product offerings and integration opportunities and timing. Each of the forward-looking statements is subject to change based on various important factors, including without limitation: the successful integration of Chiltern into LabCorp’s business; adverse reactions to the integration by customers, suppliers or strategic partners; dependence on key personnel and customers; reliance on proprietary technology; management of growth and organizational change; and competitive actions in the marketplace. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC.
|Print Page | E-mail Page | RSS Feeds | E-mail Alerts | IR Contacts | Tear Sheet|